240 27. Tobinai K. Current management of adult T-cell leukemia/lympho- ma. Oncology (Williston Park). 2009;23:1250–6. 28. O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9. 29. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polar- ized human type 2 Th cells. J Immunol. 1998;161:5111–5. 30. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847–53. 31. Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensiti- zation and internalization on human Th2 cells. Eur J Immunol. 2004;34:231–40. 32. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625–34. 33. Nakayama T, Hieshima K, Arao T, et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene. 2008;27:3221–32. 34. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological signifi- cance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494–500. 35. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell- associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685–90. 36. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array compar- ative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T- cell leukemia/lymphoma. Clin Cancer Res. 2009;15:30–8. 37. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4- bearing Th2 cells toward antigen-presenting cells by the CC che- mokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11:81–8. 38. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chi- meric anti-CC chemokine receptor 4 IgG1 with enhanced Curr Hematol Malig Rep (2012) 7:235–240 antibody-dependent cellular cytotoxicity shows potent thera- peutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64:2127–33. 39. Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immuno- therapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520–31. 40. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–73. 41. Yano H, Ishida T, Imada K, et al. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal anti- body in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol. 2008;140:586–9. 42. Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol. 2009;183:4782–91. 43. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and periph- eral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8. This manu- script describes the results of a phase I study of mogamulizumab (KW-0761) in ATL and PTCL, showing encouraging therapeutic efficacy with acceptable toxicity profiles. 44. Yamamoto K, Tobinai K, Akinaga S, et al. Reply to R. Suzuki. J Clin Oncol. 2010;29:8356. 45. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42. This manuscript describes the results of a phase II study of mogamulizu- mab/KW-0761 in relapsed patients with ATL, yielding a best overall response rate of 50 % and median progression-free survival of 5.2 months. 46. Duvic M, Pinter-Brown L, Foss FM, et al.: Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. [abstract 962]. Presented at the 52nd Annual Meeting of the American Society of Hematology. Orlando, USA; December 4–7, 2010.